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Abstract
Background: Low-dose-rate permanent prostate brachytherapy (PPB) is an attractive treatment option for patients
with localised prostate cancer with excellent outcomes. As standard CT-based post-implant dosimetry often
correlates poorly with late treatment-related toxicity, this exploratory (proof of concept) study was conducted to
investigate correlations between radiation − induced DNA damage biomarker levels, and acute and late bowel,
urinary, and sexual toxicity.
Methods: Twelve patients treated with 125I PPB monotherapy (145Gy) for prostate cancer were included in this
prospective study. Post-implant CT based dosimetry assessed the minimum dose encompassing 90% (D90%) of the
whole prostate volume (global), sub-regions of the prostate (12 sectors) and the near maximum doses (D0.1cc, D2cc)
for the rectum and bladder. Six blood samples were collected from each patient; pre-treatment, 1 h (h), 4 h, 24 h
post-implant, at 4 weeks (w) and at 3 months (m). DNA double strand breaks were investigated by staining the
blood samples with immunofluorescence antibodies to γH2AX and 53BP1 proteins (γH2AX/53BP1). Patient self-
scored quality of life from the Expanded Prostate Cancer Index Composite (EPIC) were obtained at baseline, 1 m,
3 m, 6 m, 9 m, 1 year (y), 2y and 3y post-treatment. Spearman’s correlation coefficients were used to evaluate
correlations between temporal changes in γH2AX/53BP1, dose and toxicity.
Results: The minimum follow up was 2 years. Population mean prostate D90% was 144.6 ± 12.1 Gy and rectal near
maximum dose D0.1cc = 153.0 ± 30.8 Gy and D2cc = 62.7 ± 12.1 Gy and for the bladder D0.1cc = 123.1 ± 27.0 Gy and
D2cc = 70.9 ± 11.9 Gy. Changes in EPIC scores from baseline showed high positive correlation between acute toxicity
and late toxicity for both urinary and bowel symptoms. Increased production of γH2AX/53BP1 at 24 h relative to
baseline positively correlated with late bowel symptoms. Overall, no correlations were observed between dose
metrics (prostate global or sector doses) and γH2AX/53BP1 foci counts.
Conclusions: Our results show that a prompt increase in γH2AX/53BP1foci at 24 h post-implant relative to baseline
may be a useful measure to assess elevated risk of late RT − related toxicities for PPB patients. A subsequent
investigation recruiting a larger cohort of patients is warranted to verify our findings.
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Background
Prostate cancer is the most commonly diagnosed
male cancer in the UK with an incidence of 103 cases
per 100,000 (European age-standardised rates, 2010)
and almost 47,300 patients were diagnosed in the UK
alone in 2013 (Cancer Research UK). Initial treatment
options include active surveillance [1], androgen
deprivation therapy (ADT) [2], radical prostatectomy
[3], external beam radiotherapy (EBRT) and brachy-
therapy with a patient’s Gleason score and tumour
staging primarily dictating which treatment modality
is optimal. For localised prostate cancer (T1-T2, Gleason
score ≤ 7 and PSA < 20 ng/ml), low-dose-rate permanent
prostate brachytherapy (PPB) is an attractive choice of
treatment due to its convenience, favourable dose distri-
bution to normal tissues, high success rate with regards to
both progression free and overall survival [4, 5] and its po-
tential higher likelihood of potency preservation when
compared to prostatectomy [6].
Current post-implant dosimetric evaluation for PPB is
calculated using CT derived models while patient out-
comes and quality of life (QoL), in the form of function
and bother, can be measured using patient − reported
outcome measures such as the Expanded Prostate
Cancer Index Composite (EPIC) questionnaire [7]. The
use of blood − derived radiation biomarkers have pro-
vided in-vivo detection of irradiation for large volume
acute radiation exposures [8–10], however their utility
for small volume prolonged PPB exposures within
brachytherapy has yet to be established. The histone
H2AX is phosphorylated to γH2AX at the sites of radi-
ation induced DNA double − strand breaks (DSBs) [11],
where it co-localises with the DNA repair protein
53BP1. Loss of γH2AX/53 PB1 over time correlates well
with the kinetics of DSBs repair, and has been exten-
sively used to probe the kinetics of repair in a range of
conditions [11–15]. γH2AX/53BP1 form distinct nuclear
foci which can be readily detected and quantified using
immunofluorescence microscopy. For acute doses, a
minimum sensitivity down to 5 mGy was detected in pa-
tients undergoing a chest CT by comparing pre- and
post- CT γH2AX foci numbers in peripheral blood lym-
phocytes [16]. With low background numbers of DSBs
and a well characterised radiation response, peripheral
blood lymphocytes are well established as an ideal ex-
vivo cell model to use for biological dosimetry.
The level of detectable DNA damage in the lympho-
cyte population, which contains cells constantly circu-
lating throughout the peripheral blood and also
stationary in reservoirs throughout the body such as
lymph nodes and spleen, may not correlate simply to
the equivalent whole body dose delivered to the pa-
tient. There is also increasing evidence that doses re-
ceived by the prostate and surrounding organs such as
the bladder and rectum will display varying degrees of
inter- and intra-patient variability [17, 18]. Whether
radiation induced DNA damage to the lymphocyte
population is dependent on where doses are targeted
rather than simply the total dose delivered to all tis-
sues is currently poorly understood.
The primary objective of this study was to investigate
and quantify, for the first time, the induction and per-
sistence of γH2AX/53BP1 foci in peripheral blood lym-
phocytes in patients undergoing low-dose-rate PPB for
prostate cancer. Furthermore, we tested the hypothesis
that levels of biological DNA damage biomarkers rela-
tive to baseline would correlate with patient reported
QoL outcome measures determined using the EPIC
questionnaire.
Methods
Patient cohort
Following ethical approval, 12 patients eligible for
treatment with PPB for prostate cancer were identified
and recruited for this study. Patients’ baseline charac-
teristics are presented in Table 1. Written information
was provided and potential subjects were given at least
7 days to decide upon participation. Inclusion criteria
were as follows; patients with histologically confirmed
adenocarcinoma of the prostate, who elected for low-
dose-rate permanent prostate brachytherapy, WHO
performance status 0 – 2, life expectancy of at least
12 months, age ≥ 18 years and a willingness to co-
operate with follow-up. Exclusion criteria were; chronic
bowel disorder or previous bowel surgery, rheumatoid
arthritis, auto immune disease, an active bacterial, viral
or fungal infection, renal impairment, diabetes or pre-
vious radiotherapy.
Table 1 Patient basic baseline characteristics
Patient # Age at
diagnosis
PSA
(ng/mL)
Gleason
(primary + secondary)
Risk
group
1 60 9.2 3 + 4 2
2 58 9.7 3 + 4 2
3 60 10.9 3 + 3 2
4 55 8.6 4 + 3 2
5 55 9.2 3 + 3 1
6 51 8.7 3 + 4 2
7 54 6.7 4 + 3 2
8 74 7.4 4 + 3 2
9 57 7.7 3 + 4 2
10 65 14.5 4 + 3 2
11 53 3.9 3 + 4 2
12 57 11.6 3 + 4 2
Risk group 1 = low risk, 2 = intermediate risk
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Planning
Prior to implantation, all patients underwent a detailed
prostate volume study using a bi-planar trans-rectal
probe 8848 (BK Medical Systems Inc. Washington, MA).
All implants were planned using 125I stranded radio-
active seeds with a reference air kerma rate of 0.458 –
0.496 U (U –μGyh−1m2) [19, 20]. The half-life of Iodine
125 is 59.43 days. The American Association of
Physicists in Medicine Task Group 43 (TG-43 update)
formalism was used in the planning and calculation of
the final dosimetry [21]. All treatment plans were cre-
ated to meet the objectives and constraints recom-
mended by ESTRO/EAU/EORTC guidelines [22]. A
Variseed 8.0 (Varian Medical Systems, Charlottesville,
VA) treatment planning system (TPS) was used for both
pre- and post- implant planning. The minimum pre-
scription dose was 145 Gy for all patients, representing
the planned dose that will encompass the entire target
volume. The dose inside the target volume will be
>145Gy, therefore planning constraints are used; no
more that 55% of the target volume may receive ≥150%
of dose (217.5Gy) and the volume receiving ≥200%
(290Gy) should be limited to ≤ 20%. Post-implant CT
scans (2.5 mm slice thickness) were obtained four weeks
after implantation. CT scans were then transferred to
the TPS and the structures including prostate, bladder and
rectum were delineated. Although a pre-implantation plan
is created to ensure 100% dose to the planning target
volume, the practicalities of inserting needles into the
prostate together with post-surgical oedema and seed mi-
gration can result in differences between the intended and
delivered dose [23–25]. With this information, a dose dis-
tribution for each organ can be created for each patient;
Fig. 1 is a typical example.
Post-implant dosimetry was evaluated for whole pros-
tate (global) minimum dose to 90% of prostate (D90%)
and the maximum dose, 0.1 cc (D0.1cc(Gy)) and 2 cc
(D2cc (%)), received by the rectum and bladder. These
point doses represent the highest dose delivered to the
identified organ at risk and are described as by either ab-
solute dose in Gy or as percentage of the prescribed
dose and allow uniform comparison of acute and late
toxicity to organ at risk dosimetry. In addition, sector
analysis of 12 prostatic regions (sectors) was conducted.
As described in more details in previous publications
[25, 26], sector analysis involved dividing the prostate
into three equal lengths along the cranio-caudal axis to
create base, mid-gland and apex, then sub-dividing with
a vertical plane and a horizontal plane creating right/left
anterior and right/ left posterior sectors (also see
Additional file 1: Figure S1). D90% was then determined
for each sector of the prostate.
γH2AX and 53BP1 detection
In all the cases, peripheral venous blood was sampled in
an EDTA tube and placed immediately on ice prior to
Fig. 1 Typical dose distribution following 125I prostate brachytherapy. The rectum, prostate and bladder have been contoured on a CT scan
4 weeks after brachytherapy and reconstructed in 3D. Brachytherapy seeds within the prostate are highlighted green and a colourwash
representing total dose has been applied to the surface of each organ
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transfer for analysis. For each patient, a sample was
taken prior to brachytherapy to acquire a baseline and
succeeding samples were gathered at 1 h, 4 h, 24 h,
4 weeks and 3 months post-seed implantation (a total of
6 blood samples for each patient). Blood samples at
4 weeks were always collected just before the acquisition
of post-implant CT scans.
Separation of lymphocytes for γH2AX /53BP1 foci analysis
4 ml of whole blood was pipetted onto 3 ml of Ficoll-
Plaque (GE Healthcare) and centrifuged at 4 oC, 400G,
for 30 min. 1 ml of separated lymphocytes were aspi-
rated and mixed with 10 ml of sterile phosphate buffered
saline (PBS) to wash. The lymphocyte suspension was
centrifuged at 4 oC, 100 g, for 20 min to form a cell pel-
let. The remaining PBS was decanted and the pellet re-
suspended with 1 ml of fresh sterile PBS.
Fixation, staining of PBLs for γH2AX and 53BP1 foci
100 μl of re-suspended lymphocytes were loaded onto
Superfrost Plus (VWR international) glass slides by cyto-
spinning at 500 g for 10 min. The cells were then fixed
with 4% formaldehyde at room temperature for 10 min.
Each slide was then washed 3 times with PBS. The cells
were permeabilized with a 0.5% (v/v) solution of Triton-
X/PBS for 10 min. Blocking was achieved with 1% BSA
in PBS for 1 hour at room temperature. Cells were then
incubated for 1 h at room temperature with a solution
of 1:5000 Mouse anti SER 139 H2AX (Millipore) and
rabbit anti 53BP1 (Novus biologicals) in 0.05% Triton-X/
PBS. Cells were then washed with 0.05% Triton-X/PBS.
Secondary antibodies 1:2000 of goat anti-mouse Alexa-
fluro 488 (Invitrogen) and goat anti rabbit 53BP1 in
0.05% Triton-X/PBS were applied for a further 1 h at
room temperature. Cells were then washed with 0.05%
Triton-X/PBS and air dried at room temperature. The
slides were mounted with Prolong Antifade Gold with
DAPI (Life Technologies) and coverslip.
Visualisation and counting of foci
Cells were visualised (by a single observer) using a
Nikon fluorescent microscope at x63 magnification.
Lymphocytes were identified by morphology after DAPI
staining, other cell types were excluded from counting.
γH2AX foci co-localising with 53BP1 foci were counted
by eye in 200 cells for each time point.
Health related quality of life endpoints
Heath related QoL was assessed using the Expanded
Prostate Cancer Index Composite (EPIC) instrument [7].
The EPIC questionnaire is divided into domains related
to bowel, urinary, sexual and hormonal toxicities. Each
domain is divided into functional and bother scores
which can be combined to produce a summary score.
For this study, bowel, urinary and sexual summary
scores were assessed. A score of 100 indicates no prob-
lem; lower values indicate complications. For each pa-
tient, EPIC scores were obtained at baseline (pre
brachytherapy), 1 month (m) post-brachytherapy, 3 m,
6 m, 9 m, 1 year (y), 2y and 3y. Primary endpoints were
bowel-, urinary- and sexual- related toxicities after
brachytherapy. Change-from baseline analysis was con-
ducted using the EPIC scores. Acute toxicity was defined
as those events (i.e. decrease of score from baseline) that
presented within the first 3 months following treatment.
Late toxicity was defined as events that developed at any
time after treatment and not resolved at 2–3 years after
treatment.
Statistical analysis
All correlation analysis was conducted in R (version
3.2.0) using Spearman’s correlation testing at a signifi-
cance level p ≤0.05. Although multiple comparisons
were conducted, no corrections were applied due to the
exploratory/feasibility nature of this study (also see re-
lated section in the discussion). Moreover, to test if foci
distributions corresponded to a Poisson distribution at
each time-point, χ2 testing was used with a significance
threshold of p = 0.05.
Results
γH2AX and 53BP1 foci induction
Prior to implantation of 125I seeds into the prostate,
mean (±SD) background foci (co-localising γH2AX/
53BP1) was measured at 0.42 ± 0.20 foci per cell, ranging
from 0.11 to 0.72 (Fig. 2b). A Shapiro-Wilk test
confirmed the data was normally distributed (w = 0.943,
p = 0.540). Following seed implantation, γH2AX/53BP1
foci numbers were significantly elevated as early as 1 h
post-implantation (paired t-test p < 0.001), and remained
significantly higher than background levels at 4 and
24 h, 4 weeks and 3 months post-implantation (Fig. 2b).
Fig. 2c shows the mean number of foci per cell corrected
for background.
The highest foci numbers were observed 4 weeks
(672 h) after irradiation, at 1.1 ± 0.1 foci per cell. This
value is more than 2.5-fold above background foci levels
(0.4 ± 0.1) and is significantly higher than 24 h values
(paired t-test p = 0.02), suggesting that brachytherapy
acts as a significant additional source of genetic stress in
these lymphocytes. Based on ex vivo lymphocyte studies
[11] showing an average of 15.5 foci induced per Gy with
an average half-life of 2 h, an average of 0.7 excess foci
per cell corresponds to an average dose-rate to the
lymphocyte population of 4.5 cGy/h. Interestingly, this
dose rate is comparable to the initial dose rate delivered
to the prostate, 7.1 cGy/h (Additional file 2: Figure S2),
despite the majority of lymphocytes not being within the
Osman et al. Radiation Oncology  (2017) 12:53 Page 4 of 12
exposed volume at any given time. This suggests either
the impact of other stresses on lymphocyte DNA dam-
age levels, or the formation of DSBs with a long half-life.
This is further supported by the observation that
γH2AX/53BP1 foci numbers continued to rise at 4 weeks
(672 h) even after reduction in seeds activity due to
natural decay (Fig. 2a), and showing only limited
(statistically insignificant) decline at 3 months despite
source activity falling by almost three-quarters.
As the increase in mean foci counts over time may
have been due to an increased proportion of observed
cells with foci or greater foci numbers in irradiated cells,
the relative frequency distribution of foci per lymphocyte
over time was plotted (Fig. 3). It can be seen that, at all
time-points post-implantation, there is a gradual increase
in both the number of hit cells, and the number of cells at
each foci level, indicating some increase in damage in
large number of cells rather than the presence of a small
subpopulation of highly damaged cells. At no time point
did more than 1% of all cells show more than 7 foci. How-
ever, while this damage may have been expected to follow
a Poisson distribution, all foci distributions are signifi-
cantly different to that predicted by a Poisson distribution
(p < 0.0001), with an excess of undamaged cells, suggesting
some degree of mixing between populations exposed to
different stresses.
QoL scores over time
As demonstrated in Fig. 1, the main neighbouring or-
gans at risk which receive high dose in prostate brachy-
therapy are the prostate, urethra, rectum and bladder
and toxicities observed in patients undergoing brachy-
therapy are usually related to these organs. QoL in terms
of patients’ bowel, urinary and sexual health was mea-
sured using the EPIC questionnaire before seed-
implantation and up to three years post-treatment. In-
creased toxicities were observed post-implant peaking at
6 m for bowel symptoms (Fig. 4a), and at 1 month post-
implant for both urinary (Fig. 4b) and sexual (Fig. 4c)
symptoms.
Global analysis
Population median prostate global D90% was (median
(range)) 144.4 Gy (range: 125.4 Gy −160.3 Gy). The
median of the highest point dose within the contoured
rectum represented by D0.1cc was 145.2 Gy (range:
112.5 Gy – 212.5 Gy) and the highest dose delivered to a
2 cc of the rectum (D2cc) was 62.0% (range: 42.4% –
84.8%). Bladder median D0.1cc was 123.0 Gy (81.3 Gy −
180.3 Gy) and D2cc =70.4% (54.0% − 91.7%).
Fig. 2 a) Relative activity of 125I as a function of time post-seed-
implantation. b) mean foci number per cell in patients' peripheral
blood lymphocytes (the blue square on the vertical axis indicates
mean background counts) and corrected for background (c). The
error bars represent the standard error and the red dashed line
represents the 125I half-life of 1426.3 h (59.43 days)
Fig. 3 Foci distribution counts in patients’ peripheral blood
lymphocytes pre- and post- seed implantation. The error bars
represent the standard error
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Foci count, EPIC, sector analysis and dosimetric
parameters: initial exploratory correlation analysis
Statistical correlation testing was conducted to explore
potential signals of associations between the biological,
patient − reported symptoms and dosimetric parameters
using Spearman rank correlation coefficients. The results
are presented in Figs. 5, 6 and 7. Background foci counts
as well as the ratios at time point (t) relative to back-
ground (foci count prior to brachytherapy) are pre-
sented. Strong positive correlations were observed
between mean foci counts at 24 h post-implantation and
bowel toxicity at 1y and 2y, Fig. 5. This suggest that the
larger the number of foci developed 24 h post-implant
the more bowel symptoms the patients experienced.
Although not statistically significant, a trend of positive
correlations was also observed between the maximum
dose to the rectum (rectum D0.1cc and D2cc) and late
bowel toxicity. Several sector doses also correlated with
early γH2AX/53BP1 foci counts (see Figs. 5, 6 and 7)
but these correlations were not significant.
Discussion
By use of DNA DSB markers γH2AX and 53BP1, gamma-
ray induced DSBs in peripheral blood lymphocytes of
prostate cancer patients undergoing brachytherapy with
125I seeds can be readily visualised and quantified. X-ray
induced DSBs have been detected numerous times in pa-
tients receiving EBRT [8, 9, 27, 28]. Moreover, in the field
Fig. 4 Changes in quality-of-life scores over time for each domain studied on the Expanded Prostate Cancer Index Composite (EPIC) questionnaire.
EPIC scores range from 0 to 100, with higher values representing a more favorable health-related quality of life. In the figure median with inter-quartile
range IQR (boxes), and ± 1.5*IQR (whiskers) are presented. Dots are different data points and red dots are outliers
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of nuclear medicine, Lassmann and colleagues have inves-
tigated the kinetics of γH2AX/53BP1 foci in peripheral
leukocytes and lymphocytes in thyroid cancer patients be-
ing administered either 177Lu or 131I up to 144 hours post-
infusion [12, 29, 30]. However, to our knowledge, this is
the first study to demonstrate elevated DSBs in circulating
lymphocytes in permanent prostate brachytherapy treat-
ment and to study the kinetics of foci production in rela-
tion to late toxicity.
Lymphocytes within the peripheral blood circulation
exist in equilibrium with large reservoirs of lymphocytes
within the lungs and within extra vascular lymphatic tis-
sue such as lymph nodes, the spleen and Peyer’s patches
[31, 32]. Using ex-vivo FITC-labelled lymphocytes
injected intravenously into sheep, Andrade et al. found
these peripherally derived lymphocytes reached equi-
librium with exchange to lymph tissue four hours
post-injection [33]. Thus, at any given time, foci num-
bers measured in peripheral lymphocytes is a combin-
ation of both un-irradiated lymphocytes as well as
those which have been irradiated by passing near the
prostate at a range of earlier times. Redistribution of
PBLs between intra and inter vascular spaces would
be expected to reduce observed mean foci counts and
increase the number of undamaged cells observed at
early time points.
As expected, in the first hours post-implant an in-
crease in foci count is observed, as levels of damage
within the cells build up until the rate of repaired foci
matches the induction of new damage by the radio-
nuclide source. This process would be expected to reach
equilibrium in a timeframe similar to that seen for DSB
repair and PBL redistribution, both of which are typically
on the order of a few hours. However, continual in-
creases in DSB foci level are seen out to 24 hours and
even four weeks post-implantation.
The continued increase to multiple weeks is particu-
larly significant as by this time decay has reduced the ac-
tivity of sources by more than a quarter. This persistent
increase in damage is indicative of either extremely
long-lived DNA damage within a proportion of PBL, or
another effect increasing the rate of DSB induction even
Fig. 5 Bowel-related cross-correlation matrix of Spearman’s correlation coefficients (ρ). Upper triangle; ρ values with insignificant correlation
(p ≤ 0.05) marked with an X. Lower triangle; colour coded coefficients. S(x) = prostatic sector number ‘x’, Rec = rectum, D0.1cc and D2cc = the doses
received by the hottest 0.1 cc and 2 cc of the volume, respectively. Foci base = γH2AX/53BP1 foci count at baseline (pre-implant (t = 0 h)). Foci R
t = ratio of foci count at time point t relative to baseline (0 h). EPIC(x) = change in EPIC score from baseline; positive values reflecting improvement,
negative values deterioration and 0 no change. * For space consideration all ρ values are presented as percentages
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as the source decays. Foci kinetics at extremely long
time points are poorly studied in lymphocytes, while the
existence of fast and slow components of DNA repair
are well established with reports of slow repair with half-
lives of 38 hours [11]. It is possible to speculate that the
current study is highlighting a proportion of DSBs
repaired even slower or which totally failed to repair.
Similarly, the effect of radiation on the distribution of
lymphocytes between vascular and extra vascular − com-
partments is unknown. It is increasingly recognised that
radiation derives an inflammatory response increasing
lymphocytic infiltration in target tissues [34]. Any in-
crease in PBL flow through the prostate would lead to a
greater effective dose being seen by the lymphocytes, in-
creasing the number of damaged cells and average foci
numbers. Determining which of these effects dominates
PBL foci kinetics requires further study.
One advantage DSB foci counting provides is that the
dose received by the different structures (via DSBs) is
over an integrated time post-implantation, whereas the
post-treatment planning CT is a single snap shot of a
patient’s physiology weeks later. The conventional
method uses post-implant dose to predict radiation in-
duced damage. An alternative method to assess radiation
induced damage directly may lie in the ratio of foci ob-
served between 0 h (and 4 h) and 24 h post − seed
implantation.
In this study, positive correlations were found between
increased early γH2AX/53BP1 foci production (24 h)
and late bowel toxicity (EPIC 1y) (p = 0.035), EPIC 2 y
(p = 0.001). Similar positive correlations were observed
between increased foci count at 1 m relative to baseline
and late bowel toxicity ((EPIC 1 y (p = 0.046), EPIC 2 y
(p = 0.0189)).
Moreover, urinary toxicity positively correlated with
the increase in doses received by prostatic base (sector
3, 4), D90% and the maximum dose received by the hot-
test 2 cc of the bladder. These observations are in agree-
ment with results published by Hathout et al. that the
dose received by the bladder neck had a strong prog-
nostic power for both early and late toxicity [35]. It
may be that the region of bladder irradiation plays an
Fig. 6 Bladder-related cross-correlation matrix of Spearman’s correlation coefficients. (ρ). Upper triangle; ρ values with insignificant correlation
(p ≤ 0.05) marked with an X. Lower triangle; colour coded coefficients. S(x) = prostatic sector number ‘x’, Bla = bladder, D0.1cc and D2cc = the doses
received by the hottest 0.1 cc and 2 cc of the volume, respectively. Foci base = γH2AX/53BP1 foci count at baseline (pre-treatment (t = 0 h)). Foci
R t = ratio of foci count at time point t relative to baseline (0 h). EPIC (x) = change in EPIC score from baseline; positive values reflecting improvement,
negative values deterioration and 0 no change. * For space consideration all ρ values are presented as percentages
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important role in predicating toxicity alongside both
total dose and volume irradiated. Urethral toxicity is
likely to dominate urinary toxicity, especially in
brachytherapy patients [36]. For bladder and rectal
doses, it’s expected that these organs will move and
change position quite frequently during treatment, for
example, due to bladder filling and emptying [37] and
small bowel peristalsis, potentially significantly altering
the prescribed dose received to either or both organs.
Prostatic sector 6 dose positively correlated with in-
crease in sexual symptoms at all times. Significant
strong positive correlations were found between late
and early urinary symptoms (Fig. 6). Similar correla-
tions were also found for bowel toxicity (Fig. 5) but
not for sexual symptoms (Fig. 7).
Several articles have demonstrated the association be-
tween late normal tissue toxicity after EBRT and insuffi-
cient repair of DNA double − strand breaks in breast,
head and neck and prostate cancer [38, 39]. In a study
investigating DNA damage response as a possible risk
factor for late toxicity in prostate cancer (n = 61), van
Oorschot et al. found no significant differences between
patient’s γH2Ax immediately after RT [40]. However,
significant differences in foci decay (at 24 h post-
irradiation) were observed between radio-sensitive and
radio-resistant prostate cancer patients [40]. This implies
that less efficient repair of radiation − induced DSBs may
contribute to the development of late toxicity. These ob-
servations have great potential in the field of personal-
ized medicine as for many years different tests have been
proposed to investigate individual patient sensitivity to
RT.
Several studies have shown that γH2AX could be used
for in-vivo dose estimation for EBRT [27, 28]. In con-
trast with EBRT, the dose delivered in brachytherapy is
more confined to the prostate and it accumulates over a
period of time. Moreover, in general, smaller patient’s
volumes are exposed to radiation compared to EBRT.
Therefore, unsurprisingly our results in this study for
brachytherapy indicate a lack of correlation between foci
Fig. 7 Sexual symptoms-related cross-correlation matrix of Spearman’s correlation coefficients (ρ). Upper triangle; ρ values with insignificant
correlation (p≤ 0.05) marked with an X. Lower triangle; colour coded coefficients. S (x) = prostatic sector number ‘x’. Foci base = γH2AX/53BP1 foci
count at baseline (pre-treatment (t = 0 h)). Foci R t = ratio of foci count at time point t relative to baseline (0 h). EPIC (x) = change in EPIC score
from baseline; positive values reflecting improvement, negative values deterioration and 0 no change. * For space consideration all ρ values are
presented as percentages
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counts at different time points and dosimetric measures
as the radiobiological effect is different compared to
EBRT.
As early identification of patients with high risk of
toxicity is of clinical importance, we investigated ini-
tial DNA damage foci production in relation to late
toxicity. Strong positive correlations were found be-
tween early foci production ratios (relative to base-
line) and late rectal toxicity. If this finding is
validated in future clinical studies, this assay could
have clinical utility as methods to reduce rectal dose
using, for example, peri-rectal hydrogel spacers for
patients with high levels of circulating DSBs at early
time-points after seed implant [41].
The authors acknowledge the limitations of the study
with the small number of patients and the multiple
comparisons conducted. There are many methods to
adjust for multiple comparisons (e.g. Bonferroni cor-
rection, Ducan’s multiple range tests), however, it is
overly conservative to apply these methods in the
current exploratory study [42]. The results from this
study can be used to help to generate hypotheses for
testing in larger clinical trials. Furthermore, future in-
vestigations on the relationship between DNA damage
markers γH2AX/53BP1 and other markers e.g. citrul-
line, ceramide, cytokines (CXCL1, CXCL6, CXCL8,
CXCL10, TNFα)), at specific time points may be ne-
cessary to gain more insight into the mechanisms re-
sponsible for the observed PBL foci kinetics and the
associated toxicities.
Conclusion
For the first time, we have demonstrated the detection
and temporal changes of γH2AX/53BP1 DSB foci in per-
ipheral blood lymphocytes for men treated with 125I per-
manent prostate brachytherapy. Radiation − induced
γH2AX/53BP1 levels continue to increase for four weeks
after seed implant and appear to reach equilibrium at
less than 3 m where a clear repair signal was detected.
In this small cohort of patients, levels of DSBs 24 h
post-PPB seed implant positively correlated with late
bowel toxicity. However, these findings require valid-
ation in larger patient cohorts to detect correlations with
greater certainty.
Additional files
Additional file 1: Figure S1. Twelve-sector analysis created by dividing
the prostate into three equal lengths along the cranio-caudal axis to form
the base, mid-gland, and apex and then subdivide with vertical and
horizontal plans generating right/left posterior sectors (reused from (21)
with permission from AB Mohamed Yoosuf). (PDF 61 kb)
Additional file 2: Figure S2. Top; dose rate (cGy/h) as a function of
time since implant for 125I monotherapy plotted using the equation, Dose
rate tð Þ ¼ mPD ln2t1=2
 
:2
t
t1=2
 
, where t is the elapsed time, mPD is the
minimum peripheral dose (=145 Gy for 125I) and t1
2= is the half-life
(=59.43 days for 125I). Bottom; the time required to deliver relative fraction
of the prescribed dose, Fractional dose tð Þ ¼ 1−e−
t: ln2
t1=2
 
. Reference: Dale
RG. The applications of the linear-quadratic dose effect equation to
fractionated and protracted therapy. Br J Radiol 1985; 58: 515–28.
(PDF 178 kb)
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